- Home
- DAVE vs RNA Comparison
DAVE vs RNA Comparison
Compare DAVE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- RNA
- Stock Information
- Founded
- DAVE 2017
- RNA 2012
- Country
- DAVE United States
- RNA United States
- Employees
- DAVE N/A
- RNA N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- RNA Health Care
- Exchange
- DAVE Nasdaq
- RNA Nasdaq
- Market Cap
- DAVE 3.4B
- RNA 4.0B
- IPO Year
- DAVE N/A
- RNA 2020
- Fundamental
- Price
- DAVE $185.81
- RNA $70.90
- Analyst Decision
- DAVE Strong Buy
- RNA Buy
- Analyst Count
- DAVE 6
- RNA 20
- Target Price
- DAVE $282.17
- RNA $69.26
- AVG Volume (30 Days)
- DAVE 571.4K
- RNA 10.2M
- Earning Date
- DAVE 11-04-2025
- RNA 11-10-2025
- Dividend Yield
- DAVE N/A
- RNA N/A
- EPS Growth
- DAVE 224.46
- RNA N/A
- EPS
- DAVE 10.12
- RNA N/A
- Revenue
- DAVE $491,301,000.00
- RNA $20,868,000.00
- Revenue This Year
- DAVE $50.20
- RNA N/A
- Revenue Next Year
- DAVE $15.33
- RNA $108.97
- P/E Ratio
- DAVE $20.29
- RNA N/A
- Revenue Growth
- DAVE 53.84
- RNA 106.27
- 52 Week Low
- DAVE $65.46
- RNA $21.51
- 52 Week High
- DAVE $286.45
- RNA $71.09
- Technical
- Relative Strength Index (RSI)
- DAVE 36.65
- RNA 80.22
- Support Level
- DAVE $215.00
- RNA $70.59
- Resistance Level
- DAVE $249.00
- RNA $71.09
- Average True Range (ATR)
- DAVE 23.78
- RNA 0.29
- MACD
- DAVE -5.51
- RNA -0.36
- Stochastic Oscillator
- DAVE 6.85
- RNA 80.82
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.